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INCREASED LEVELS OF 
ENDOTHELIN-1 IN 
BRONCHOALVEOLAR 
LAVAGE FLUID OF PATIENTS 
WITH LUNG ALLOGRAFTS 
The aim of the present study was to determine levels of endothelin-1 in 
bronchoalveolar lavage fluid and in plasma in patients with lung and 
heart-lung allografts. The aim was based on the hypothesis that levels of 
endothelin-1 are elevated in the bronchoalveolar lavage fluid of patients 
with lung allografts. Patients (n = 23) undergoing heart-lung (n = 8), 
single-lung (n = 10), or bilateral lung (n = 5) transplantation were 
included in the study. In patients with single-lung allografts, endothelin-1 
levels were analyzed in bronchoalveolar lavage fluid from both the trans- 
planted and the nontransplanted, native lung. The level of endothelin-1 was 
also analyzed in bronchoalveolar lavage fluid from 12 patients who did not 
undergo transplantation. Transbronchial biopsies and bronchoalveolar 
lavage were done routinely or when clinically indieated on 64 different 
occasions, between 2 and 104 weeks after transplantation. The level of 
endothelin-1 was measured in bronchoalveolar lavage fluid and plasma by 
radioimmunoassay. Immunoreactive endothelin-1 was detectable in bron- 
choalveolar lavage fluid from all patients. The concentration of endothe- 
lin-1 in bronchoalveolar lavage fluid from transplanted lungs (2.94 + 0.30 
pg/ml, n = 64) was significantly higher compared with that in bronchoal- 
veolar lavage fluid from patients without allografts (0.86 _ 0.20 pg/ml, n = 
12, p < 0.01). In patients who received single-lung transplantation because 
of emphysema, °the level of endothelin-1 in bronchoalveolar lavage fluid 
from the transplanted lung was significantly greater than that from the 
native lung (5.61 - 1.9 versus 0.39 - 0.05 pg/ml, p < 0.05). Concentrations 
of endothelin-1 in bronchoalveolar lavage fluid did not correlate with grade 
of rejection, infection, or time after transplant. Plasma levels of endothe- 
lin-1 were unchanged with pulmonary rejection. These results indicate that 
endothelin-1 is released into bronchi of transplanted human lungs. The 
release is not associated with rejection or infection. Because of its potent 
mitogenic properties, endothelin-1 may have a potential impact in the 
development of posttransplant complications such as bronchiolitis obliter- 
ans. (J THORAC CARDIOVASC SURG 1996;111:253-8) 
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E ndothelin-1 (ET- l )  is a bioactive 21-amino-acid peptide produced by vascular endothelial cells, 1 
bronchial epithelium, 2' 3 and mononuclear cells such 
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as macrophages and lymphocytes. 4 In addition to 
causing bronchoconstriction a d vasoconstriction it 
is also a mitogen and stimulates vascular smooth 
muscle and fibroblasts to proliferate. 5-8 The effects 
of ET-1 could therefore be associated with in- 
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Table I. Clinical data 
Mean age 
Transplantation in years 
Diagnosis n procedure (fange) 
Eisenmenger syndrome 5 Heart-lung 21 (16-31) 
Emphysematous disease 10 Single lung 49 (36-56) 
Primary pulmonary hy- 3 Bilateral lung 47 (33-56) 
pertension 
Cystic fibrosis 2 Heart-lung 35 (21-46) 
Bronchiectases 1 Bilateral lung 
Dilated cardiomyopathy 2 Heart-lung 34 (16-52) 
creased airway pressure and vascular esistance ob- 
served during acute lung allograft rejection and with 
the development of bronchiolitis obliterans, which is 
the most serious threat o long-term survival in lung 
recipients. 9 
In patients with symptomatic asthma 1° and pa- 
tients with interstitial ung disease TM 12 ET-1 is in- 
creased in bronchoalveolar lavage (BAL) fluid. 
ET-1 levels also increase in BAL fluid during acute 
rejection in dogs with allografts, an effect that 'is 
reversible with antirejection therapyJ 3 ET- l - l ike 
immunoreactivity in vascular endothelial and bron- 
chial epithelial cells is increased in human trans- 
planted lungs during acute rejection) 4 Therefore 
there is strong evidence that pulmonary dysfunction 
and disease are accompanied by increased release of 
ET-l ,  and the hypothesis of this study is that ET-1 
levels are elevated in BAL fluid of patients with lung 
allografts. The aim of this study was to systemati- 
cally measure ET-1 in BAL fluid and in plasma from 
human lung transplant recipients and to determine 
whether the content of ET-1 correlated with epi- 
sodes of rejection or infection. ET-1 was also inves- 
tigated in BAL fluid from subjects who did not 
undergo transplantation or operation. 
Patients and methods 
During the period November 1991 to December 1993, 
23 patients undergoing bilateral lung (n = 5), heart-lung 
(n = 8), or single-lung (n = 10) transplantation were 
included in the study. The patients' ages ranged from 16 to 
56 years with a mean age of 39 years (Table I). Nine 
patients were female and 14 were male. A control group 
consisting of 12 patients (10 smokers, 2 ex-smokers) 
admitted to the hospital because of symptoms of bronchi- 
tis was selected for the study. 
Oral consent was obtained from all patients before their 
participation i the study. The study was approved by the 
Ethics Committee of the Medical Faculty, University of 
Göteborg. 
Donors and recipients were matched by cytomegalovi- 
rus (CMV) serologic status. All organs were harvested in
a similar fashion. The heparinized onor was given an 
infusion of 20 ng/kg per minute of prostacyclin (prosta- 
glandin I2, Flolan) directly into the pulmonary artery until 
systemic blood pressure dropped by approximately 30%. 
Pulmonary preservation was then achieved by infusion 
of a cold flushing sotution into the donor pulmonary 
artery (60 ml/kg body weight). The flushing solution 
consisted of Euro-Collins olution to which was added 16 
mmol magnesium sulfate and 20 /~g of prostacyclin per 
liter of solution After the donor organ was removed itwas 
stored in cold Ringer's solution (4 ° C). All procedures 
used the same technique for extraction and implantation, 
with a running suture of nonabsorbable monofilament 
used for the airway and vascular anastomoses. In the 
single and bilateral lung procedures, the bronchial anas- 
tomosis was wrapped with an intcrcostal muscle pedMe. 
Extracorporeal circulation was necessary for intraopera- 
tive cardiopulmonary support in three patients undergo- 
ing bilateral transplantation. 
Immunosuppression. Patients received preoperative 
immunosuppression therapy with a loading dose of cyclo- 
sporine A (6 to 8 mg/kg) and azathioprine (4 mg/kg) 
orally. In addition rabbit antithymocyte globulin (Pasteur 
Merieux, 2.5 mg/kg) was used for induction immunosup- 
pression on 3 to 5 consecutive days. Methylprednisolone 
was given intravenously (500 mg at reperfusion followed 
by 125 mg every 8 hours × 3) and then continued by 
enteral administration of prednisone at a dosage of 0.3 
mg/kg per day tapered to 0.2 mg/kg per day 1 month after 
operation. Cyclosporine A was given between 12 and 24 
hours after transplantation by continuous intravenous 
infusion at a dosage adjusted to maintain serum levels of 
300 to 400 txg/L (by radioimmunoassay pecific for whole 
blood, Cyclotrac, Incstar, Minn.). As soon as enteral 
function had normalized, cyclosporine A was adminis- 
tered orally. Azathioprine was given orally once a day (2 
mg/kg) and adjusted to maintain an absolute number of 
blood neutrophils greater than 3 × 109/L. 
Episodes of acute rejection were treated with methyl- 
prednisolone (1gm) intravenously for 3 days and antithy- 
mocyte globulin therapy was reinstituted if rejection was 
resistant to steroid treatment or was particularly severe. 
Patients in the control group were not receiving medica- 
tion and therefore were free from immunosuppressive 
drugs. 
Postoperative follow-up. Transbronchial biopsies (TBBs) 
and BAL were done routinely at 2 and 4 weeks after 
transplantation and thereafter monthly for the first 3 
months. Additionally bronchoscopic studies with TBB and 
BAL were done 6, 9, and 12 months after transplantation 
or whenever indicated by clinical parameters such as 
dyspnea, hypoxemia, decline in forced expiratory volume 
in 1 second, radiographic nfiltrate, or unexplained fever. 
Repeat TBB and BAL wert done approximately 3 weeks 
after treated rejection episodes. 
The histopathologic diagnosis of rejection was deter- 
mined by TBB and graded according to the international 
working formulation for classifying and grading pulmo- 
nary rejection. 15 
BAL analyses included direct microscopy for CMV 
(intranuclear inclusions), Pneumocystis carinii (Gomori's 
silver stain), fungus, and mycobacteria and immunofluo- 
rescence microscopy for Pneurnocystis carinii, Legionella 
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Table II. ET-1 content in BAL fluid during 
episodes of acute rejection and infection in lung and 
heart-lung transplant recipients 
ET-1 
content 
n (pg/ml) 
Acute rejection 32 2.87 _+ 0.35 
Grade ! O 3.27 _+ 0.70 
Grade 2 18 2.25 _+ 0.49 
Grade 3 8 3.10 _+ 0.70 
CMV pneumonitis 5 2.71 +_ 0.54 
Bacterial infections 6 2.97 - 0.27 
Pseudomonas 1 3.90 
Enterococci 1 2.20 
Staphylococcus epidermidis 2 2.70 
Escherichia coIi 1 3.51 
Legionella 1 2.83 
No rejection/no infection 24 3.09 _+ 0.53 
r -~  
Control 
n=12 
1 
Lung-TX 
n=64 
Fig. 1. ET-1 content in BAL fluid from patients who 
underwent lung transplantation (Lung-TX) and control 
group. Levels of ET-1 were significantly increased in 
patients with allografts compared with those in control 
group. **p < 0.01. 
pneumophilia, nd respiratory syncytial virus. Polymerase 
chain reaction analysis was done for CMV 16 and culture 
for bacteri a including legionella and mycobacteria, fun- 
gus, and virus. Bacterial cultures were taken routinely 
from blood, the nasopharynx, and urine. 
Study protocol. Patients were anesthetized with intra- 
venously given propofol and the tip of the bronchoscope 
was wedged into two segmental bronchi of the lung. Saline 
solution (140 tal) warmed to body temperature was 
flushed into the bronchus. Approximately 60 to 100 ml of 
the fluid was aspirated through the suction channel of the 
bronchoscope and 10 ml was collected in chilled tubes 
containing ethylenediaminetetraacetic acid (1 mg/tal) and 
aprotinin (300 U/ml), immediately transported on ice to 
the laboratory, and centrifuged at 4 ° C, 500 gm, for 10 
minutes. The supernatant was removed with a pipette and 
frozen at -70 ° C for later analysis. 
TBB procedures were done after collection of BAL 
fluid. Biopsy specimens were taken from different sites 
within one lung with an alligator forceps: 4to 6 specimens 
were taken, immediately placed in 10% buffered formalin, 
and sent for histologic analyses. 
At the time of bronchoscopy a venous blood sample was 
taken for analysis of plasma ET-1. 
Radioimmunoassay of ET-1. Immunoreactive ET-1 
was measured with use of a double antibody kit (Amer- 
sham, RPA 545, Amersham, United Kingdom) that has 
100% crossreactivity with ET-1 and ET-2. No crossreac- 
tivity was observed with ET-3 or big endothelin. The 
towest detectable concentration for the assay was 0.33 
fmol/100 m!. 
Statistical analyses. The results are expressed as means 
plus or minus the standard error of the mean. In all 
experiments, n equals the number of samples of lavage 
fluid and blood samples obtained. Analysis of variance 
was used to compare means among the groups. When a 
significant F value was found, a Scheffe's test was used to 
identify differences among means. Values were consid- 
ered to be statistically different when p < 0.05. 
Results 
There were no deaths during the study period. In 
the 23 patients who underwent transplantation BAL 
fluid was analyzed on 64 different occasions. Pa- 
tients underwent study on at least at two different 
occasions (mean 2.8, range 2 to 6 tests per patient) 
between 2 and 104 weeks after transplantation. 
There were 32 histopathologically diagnosed acute 
rejection episodes, six episodes of bacterial infec- 
tion, and five CMV pneumonitis episodes (Table II). 
ET-1 in BAL fluifl. ET-1 was detectable in BAL 
fluid from all patients who underwent ransplanta- 
tion. ET-1 levels remained consistently high in all 
patients with a mean ET-1 content of 2.94 _+ 0.35 
pg/ml from the transplanted lungs. This was signif- 
icantly higher than ET-1 levels in the BAL fluid in 
the control group of patients who did not undergo 
transplantation (0.86 _+ 0.20 pg/ml, p < 0.01) (Fig. 
1). 
In seven single-lung transplant recipients the con- 
tent of ET-1 in the transplanted lungs was signifi- 
cantly higher than that in the native, unoperated 
contralateral lung (5.60 _+ 1.91 versus 0.39 _+ 0.05 
pg/rnl, p < 0.05, Fig. 2). The content of ET-1 in BAL 
fluid did not correlate either with the presence of 
rejection episodes or with the degree of acute 
rejection (Table II). There were no differences in 
ET-1 levels from the patients with allografts who 
had ongoing CMV infection and bacterial infections 
cornpared with levels in the absence of infection 
(Table II). 
Notably, the content of ET-1 in BAL fluid in 
patients who underwent ransplantation remained 
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Fig. 2. ET-1 content in BAL fluid from patients who 
underwent single-lung transplantation. Samples were 
taken both from native, unoperated lung and from trans- 
planted lung (Tx-lung). ET-1 levels were significantly 
increased in transplanted lungs compared with those in 
native lungs. *p < 0.05. 
high and did not decrease during the study period 
(Fig. 3). 
ET-1 in plasma. The plasma level of ET-1 during 
episodes of acute rejection in 11 patients with lung 
allografts was 1.87 ___ 0.22 pg/ml. During conditions 
of no rejection in the same 11 patients plasma ET-1 
levels were 2.24 + 0.27 pg/ml, which were not 
different from levels obtained during acute rejec- 
tion. No plasma samples were obtained from the 
control patients. 
Discussion 
Results of this study demonstrate that levels of 
ET-1 are increased in BAL fluid from transplanted 
lung allografts. Further, ET-1 levels in lavage fluid 
do not decrease with time after transplantation a d 
there is no correlation between rejection or infec- 
tion of the transplanted lung and levels of ET-1 in 
BAL fluid. 
ET-1 levels are elevated in BAL fluid from 
acutely rejecting lung allografts in dogs and pigs 13' 17 
and in rejecting lung tissue ffom human trans- 
planted lungs. 14 Therefore it is reasonable to believe 
that there is a pathophysiologic significance of the 
increased ET-1 levels in transplanted lungs. How- 
ever, the role of ET-1 as a marker of immunologic 
expression is not clear. In two experimental nimal 
studies there was a correlation between acute rejec- 
tion of the transplanted lung and release of ET-1 in 
BAL fluid. 13' 17 In the present study no such corre- 
lation was found between rejection and ET-1 levels. 
This could be explained by differences among spe- 
cies and the fact that in the animal studies lung 
4 
_ 3 
== 2 
1 
0 
0-4 4-12 
n=23 n=19 
>12 Weeks after 
n=23 transplantation 
Fig. 3. ET-1 content in BAL fluid from patients who 
underwent lung transplantation during time course after 
transplantation ranging from 2 to 104 weeks after trans- 
plantation. No significant changes in ET-1 levels were 
demonstrated during study period. 
rejection was unmodified, inasmuch as animals were 
not receiving immunosuppressive tr atment to mod- 
ify rejection. In our study all patients were given 
immunosuppressive tr atment continuously, which 
may have altered the degree and nature of ET-1 
release. 
ET-1 is a bronchoconstrictor and vasoconstrictor 
of potential pathophysiologic importance in several 
lung disorders uch as asthma 1°' 18 and cryptogenic 
fibrosing alveolitis. ]2 In guinea pigs low doses of 
ET-1 enhance the sensitivity of bronchial contrac- 
tions to histamine. 19Similarly, patients with trans- 
planted lungs have airway hyperactivity when they 
are exposed to histamine and exacerbation of these 
responses occurs during acute rejection. 2°' zl There- 
fore airway resistance and hyperactivity in patients 
with transplanted lungs may be associated with 
increased airway levels of ET-1 and the peptide 
could have a potential impact in triggering broncho- 
constriction. 
ET-1 possesses mitogenic properties and studies 
have shown that ET-1 is a mitogen for fibroblasts 
and acts synergistically to amplify the response of 
these cells to other growth factors. 22' 23 The consis- 
tently elevated levels of ET-1 from the lung al- 
lografts in the present study whether or not rejection 
or infection was present may suggest hat ET-1 
could be associated with fibroblast proliferation and 
subsequently the development ofbronchiolitis oblit- 
erans. 
The origin of ET-1 in BAL fluid is unclear but 
several sources are possible such as epithelial 
cells, 12'24 vascular endothelium, 1 macrophages, 4 
and alveolar type 2 pneumocytes. 12 The purpose of 
this study was not to investigate the pulmonary 
origin of ET-1 per se. However, the most likely 
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sources are from epithelial cells or inflammatory 
cells such as macrophages, which are the dominating 
cell population in BAL fluid and are known to 
synthesize and release ET-1. 4 Because plasma levels 
of ET-1 among the patients in this study who 
underwent transplantation were low and compara- 
ble with the range found in healthy, nonoperated 
subjects, 2s it is most likely that ET-1 is produced 
from activated immunocompetent inflammatory 
cells particularly localized in the transplanted lung. 
Glucocorticoids can induce release of ET-1. 26 
This cannot likely explain the increased levels of 
ET-1 because there was no correlation between 
ET-1 levels and the dose of corticosteroids given to 
the patients who underwent ransplantation. Fur- 
thermore, in dogs subjected to single-lung trans- 
plantation 6 days of treatment with high-dose ste- 
roids after acute lung allograph rejection decreased 
BAL fluid levels of ET-1 instead of increasing the 
release of the hormone. 13 
The release of ET-1 into the bronchial lumen may 
be the final step in a series of reactions in which a 
continuou:s inflammatory process with activation of 
inflammatory mediators uch as adhesion molecules 
and cytokines is present. Recently, a study showed 
that human lung allographs demonstrate expression 
of the cellular adhesion molecule in alveolar epithe- 
lium and vascular endothelium both in conditions of 
acute allograft rejection and when patients are free 
from rejection. 27 These findings support he hypoth- 
esis that a continuous activation of the immune 
system is present in the transplanted lung whether 
rejection is current or not. This hypothesis is sup- 
ported by, the fact that in our patients who under- 
went sing!e-lung transplantation ET-1 levels from 
the native, unoperated lungs were low and these 
lungs were not under immunoresponse tress. In the 
future, drugs that prevent he continuous immuno- 
response activation may be a new therapeutic option 
to the classi« triple-drug (steroids, cyclosporine A, 
azathioprine) regimen of patients who receive lung 
transplantation. 
In condusion, this study demonstrates a continu- 
ous release of ET-1 from the transplanted lung in 
patients with lung and heart-lung allografts. No 
correlation was found between BAL fluid levels of 
ET-t  and acute lung allograft rejection or bacterial 
or viral infection. Because ET-1 is a bioactive pep- 
tide with strong mitogenic properties the develop- 
ment of b~onchiolitis obliterans by fibroblast prolif- 
eration may in part be explained by the presence of 
the peptide in airways of lung transplant recipients. 
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